Do not lose the moon while counting the stars: Conventional IVF versus add-on treatments

Conflict of interest statement

The authors declare no conflicts of interest.

Acknowledgement

Many thanks to Orhun Isikoglu for the English language edition of the manuscript.

Funding

This study received no extramural funding.

Author’s contributions

Mete Isikoglu wrote, revised and proofread the paper.

References

[1] Lensen S, Hammarberg K, Polyakov A, Wilkinson J, Whyte S, Peate M, et al. How common is add-on use and how do patients decide whether to use them? A national survey of IVF patients. Hum Reprod 2021; 36(7): 1854-1861. doi: 10.1093/humrep/deab098.

[2] Wyns C, De Geyter C, Calhaz-Jorge C, Kupka MS, Motrenko T, et alEuropean IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). ART in Europe, 2017: Results generated from European registries by ESHRE. Hum Reprod Open 2021; 2021(3): hoab026. doi: 10.1093/hropen/hoab026.

[3] Lensen S, Osavlyuk D, Armstrong S, Stadelmann C, Hennes A, Napier E, et al. A randomized trial of endometrial scratching before in vitro fertilization. N Engl J Med 2019; 380(4): 325-334. doi: 10.1056/NEJMoa1808737.

[4] Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, et al. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med 2015; 8(1): 1286-1290.

[5] European Society for Human Reproduction and Embryology (ESHRE). Good practice recommendations for add-ons in reproductive medicine. [Online] Available from:https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Guidelines-in-development/Addons [Accessed 27 February 2023].

[6] Gleicher N, Mochizuki L, Barad DH. Time associations between U.S. birth rates and add-ons to IVF practice between 2005-2016. Reprod Biol Endocrinol 2021; 19(1):110. doi: 10.1186/s12958-021-00793-2.

[7] Human Fertilisation and Embryology Authority (HFEA). Treatment add-ons. September 25, 2019. [Online] Available from: https://www.hfea.gov.uk/treatments/explore-all-treatments/treatment-add-ons/ [Accessed 27 February 2023].

[8] Supramaniam PR, Granne I, Ohuma EO, Lim LN, McVeigh E, Venkatakrishnan R, et al. ICSI does not improve reproductive outcomes in autologous ovarian response cycles with non-male factor subfertility. Hum Reprod 2020; 35(3): 583-594. doi: 10.1093/humrep/dez301.

[9] Isikoglu M, Ceviren AK, Cetin T, Avci A, Aydinuraz B, Akgul OK, et al. Comparison of ICSI and conventional IVF in non-male factor patients with less than four oocytes. Arch Gynecol Obstet 2022; 306(2): 493-499. doi: 10.1007/s00404-022-06471-x.

[10] ASRM, Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Intracytoplasmic sperm injection (ICSI) for non-male factor indications: A committee opinion. Fertil Steril 2020; 114(2): 239-245. doi: 10.1016/j.fertnstert.2020.05.032.